Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication

Virology

Volumn 307, Issue 1, 2003, Pages 116-121

  Mansky, Louis M ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b 2078 Graves Hall ^*  (United States)

Author keywords

Drug; Evolution; Mutagenesis; Nucleoside; Polymerase

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; HYDROXYUREA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENIC ACTIVITY; MUTAGENICITY; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037343865     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(02)00069-7     Document Type: Article

References (20)

1. Bangsberg D.R., Hecht F.M., Charlebois E.D., Zolopa A.R., Holodniy M., Sheiner L., Bamberger J.D., Chesney M.A., Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 14:2000;357-366.
2. Biron F., Lucht F., Peyramond D., Fresard A., Vallet T., Nugier F., Grange J., Malley S., Hamedi-Sangsari F., Vila J. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res. 29:1996;111-113.
3. Coffin J. HIV population dynamics in vivo implications for genetic variation, pathogenesis, and therapy . Science. 267:1995;483-489.
4. Frost S.D.W., Dumaurier M.-J., Wain-Hobson S., Leigh Brown A.J. Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc. Natl. Acad. Sci. USA. 98:2001;6975-6980.
5. Garcia-Lerma J.G., Nidtha S., Blumoff K., Weinstock H., Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA. 98:2001;13907-13912.
6. Julias J.G., Kim T., Arnold G., Pathak V.K. The antiretrovirus drug 3′-azido-3′-deoxythymidine increases the retrovirus mutation rate. J. Virol. 71:1997;4254-4263.
7. Julias J.G., Pathak V.K. Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J. Virol. 72:1998;7941-7949.
8. Leigh Brown A.J. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc. Natl. Acad. Sci. USA. 94:1997;1862-1865.
9. Lori F., Malykh A.G., Foli A., Maserati R., De Antoni A., Minoli L., Padrini D., Degli Antoni A., Barchi E., Jessen H., Wainberg M.A., Gallo R.C., Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res. Hum. Retrovir. 13:1997;1403-1409.
10. Mansky L.M. Forward mutation rate of human immunodeficiency virus type 1 in a T-lymphoid cell line. AIDS Res. Hum. Retroviruses. 12:1996;307-314.
11. Mansky L.M., Bernard L.C. 3′-azido-3′-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency type 1. J. Virol. 74:2000;9532-9539.
12. Mansky L.M., Cunningham K.S. Virus mutators and antimutators roles in evolution, pathogenesis and emergence . Trends in Genetics. 16:2000;512-517.
13. Mansky L.M., Pearl D.K., Gajary L.C. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies. J. Virol. 76:2002;9253-9259.
14. Mansky L.M., Preveral S., Selig L., Benarous R., Benichou S. The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. J. Virol. 74:2000;7039-7047.
15. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:1995;5087-5094.
16. Meyerhans A., Vartanian J.-P., Hultgren C., Plikat U., Karlsson A., Wang L., Eriksson S., Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:1994;535-540.
17. Preston B.D. Reverse transcriptase fidelity and HIV-1 variation. Science. 275:1997;228-231.
18. Richman D.D. HIV chemotherapy. Nature. 410:2001;995-1001.
19. Richman D.D., Havlir D.V., Corbeil J., Looney D., Ignacio C.C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
20. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S.A., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect Dis. 6:(Suppl 3):1995;25-44.